Patent Office Rejects AcelRX's Application for Nanotab Sufentanil - 18.09.2015

Indian Patent Office has refused patent application of US-based AcelRx Pharmaceuticals, Inc, for a nanotab sufentanil,which is supposed to be administered below tongue rather than swallowing a larger pill for relief. Application failed to pass the test of Section 3(d) of Patent Act.

Tags : Indian Patent Office AcelRXNanotab Sufentanil

Share :